SEC Form 4 · accession 0001209191-17-012364
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Phillip G. Febbo
Officer — Chief Medical Officer
Period of report
Feb 15, 2017
Accepted (ET)
Feb 17, 2017 · 6:44 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 15, 2017 | F | 1,910 | $31.12 | D | 23,139 | D | |
| Common StockF2,F3,F4,F1 | Feb 16, 2017 | S | 1,269 | $29.5613 | D | 21,870 | D | |
| Common StockF2,F4,F5,F1 | Feb 16, 2017 | S | 1,226 | $30.6289 | D | 20,644 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes an aggregate of 17,800 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on November 22, 2016.
- F3Represents weighted average sale price. Actual sale prices ranged from $29.25 to $29.95.
- F4Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F5Represents weighted average sale price. Actual sale prices ranged from $30.36 to $31.02.